Reducing risk of adverse cardiovascular events, death in Type 2 diabetes

A combination treatment could be effective in treating patients with Type 2 diabetes.
In a study published in JAMA Network Open, investigators used data from Taiwan’s National Health Insurance Research Database to assess the outcomes of more than 110,000 adult patients with Type 2 diabetes who received either glucagon-like peptide-1 receptor agonists, thiazolidinediones or both between 2011 and 2020, as well as matched patients who didn’t receive the drugs.
The investigators found that the patients who received the combination of both drugs were less likely to experience all-cause mortality, cardiovascular mortality and major adverse cardiovascular events such as myocardial infarction and heart failure compared with those who didn’t receive the treatments.
The investigators emphasized that the dual therapy could provide more cardioprotective effects among the patient population with Type 2 diabetes.
Read more: JAMA Network Open
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.